Longboard Pharmaceuticals Inc (OQ:LBPH)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 02, 2024 04:01 pm ET

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 03, 2024 09:00 am ET

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an

Apr 02, 2024 04:00 pm ET

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grant

Mar 12, 2024 04:01 pm ET

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Mar 01, 2024 04:01 pm ET

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants

Feb 06, 2024 08:31 am ET

Thinking about buying stock in ZIM Integrated Shipping, Solidion Technology, SoundHound AI, Longboard Pharmaceuticals, or Xpeng?

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZIM, STI, SOUN, LBPH, and XPEV.

Feb 02, 2024 04:30 pm ET

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants

Feb 01, 2024 08:30 am ET

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

Jan 08, 2024 04:05 pm ET

Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its voting common stock, including 1,500,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at a price to the public of $21.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated off

Jan 03, 2024 09:40 pm ET

Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $210.0 million. In addition, Longboard has granted the underwriters a 30-day option to purchase up to an

Jan 02, 2024 04:01 pm ET

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $150 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchase up to an additional approximately $22.5 million of shares of voting common stock. There can be no assurance as to whether or when the

Jan 02, 2024 08:00 am ET

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathie

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT

Jan 01, 2024 04:47 pm ET

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopa

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352)

Nov 29, 2023 08:30 am ET

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting,

Nov 21, 2023 04:00 pm ET

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of

Nov 03, 2023 04:01 pm ET

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Longboard approved the grant of

Nov 02, 2023 04:01 pm ET

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 01, 2023 08:30 am ET

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

Oct 05, 2023 04:05 pm ET

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a f

Sep 19, 2023 08:30 am ET

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-c

Aug 31, 2023 04:00 pm ET

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

Aug 30, 2023 04:01 pm ET

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (A

Aug 23, 2023 08:30 am ET

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has completed enrollment of its Phase 1b/2a clinical trial, the PACIFIC Study, which is evaluating LP352, an oral, centrally acting 5-H

Aug 03, 2023 04:01 pm ET

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 03, 2023 08:30 am ET

Longboard Pharmaceuticals to Present at Upcoming Investor Conferences

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will present at the BTIG Virtual Biotechnology Conference and the Wedbush Annual PacGrow Healthcare Conference i

Jun 26, 2023 04:00 pm ET

Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will participate in a fireside chat as part of Cantor Virtual Brain Week on Friday, June 30, 2023, at 11am ET.

May 09, 2023 04:00 pm ET

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

Apr 11, 2023 04:00 pm ET

Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, Apr

Apr 05, 2023 07:00 am ET

Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352

Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Longboard Pharmaceuticals, Inc. (NASD: LBPH) to provide CDMO services. The agreement spans...

Mar 02, 2023 04:01 pm ET

Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives

Feb 23, 2023 04:31 pm ET

Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:3

Feb 10, 2023 04:01 pm ET

Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its voting common stock, including the exercise in full by the underwriters of their option to purchase an additional 750,000 shares, at a price to the public of $4.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, a

Feb 07, 2023 09:03 pm ET

Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its voting common stock at a price to the public of $4.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $20 million.

Feb 07, 2023 04:13 pm ET

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $20 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchase up to an additional approximately $3 million of shares of voting common stock. There can be no assurance as to whether or when the prop

Dec 05, 2022 08:30 am ET

Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (

Nov 29, 2022 08:30 am ET

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of

Nov 08, 2022 08:30 am ET

Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Guggenheim Healthcare Talks 4th Annual Immunology and

Nov 03, 2022 08:30 am ET